Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SurModics and X-Cell Medical form drug-eluting stent polymer matrix licensing pact:

This article was originally published in Clinica

Executive Summary

SurModics and X-Cell Medical have formed a licensing deal to use SurModics' Bravo drug delivery polymer matrix with X-Cell's Ethos drug-eluting stent (DES) for coronary use. SurModics' Bravo will be used to deliver 17 beta-oestradiol - an agent thought to reduce in-stent restenosis by suppressing neointimal hyperplasia. In addition, Princeton, New Jersey-based X-cell has completed enrolment in its ETHOS I and II clinical trials and has reported zero incidence of thrombosis thus far. SurModics, based in Eden Prairie, Minnesota has licensing agreements with seven other DES-makers.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel